Endocrine Abstracts

Introduction: Bisphosphonates therapy is the standard of care in postmenopausal osteoporosis. In the HORIZON-RFT, annual i.v. Zoledronic acid (ZOL) 5 mg infusion significantly reduced the rate of new fractures by increased bone mineral density (BMD). We proposed to evaluate the effect of ZOL treatment in BMD change in a group of postmenopausal osteoporotic women assessed by DXA–BMD. We have proposed also to assess the adverse events of this treatment.

Methods: Between 2008 and 2009 we have registered 520 postmenopausal osteoporotic women (PMOW). Among them, 22 were treated with ZOL i.v. 5 mg/yearly and 1000 mg calcium /day plus Alfacalcidol 1 μg/day for 24 months or more. DXA–BMD measurement for BMD change was used at baseline and after 12 and 24 months.

We analyzed also: changes in serum calcium, 250HD, PTH and bone alkaline phosphatase (BAP) at baseline and one and two-years post ZOL. The mean age of the patients was 64.5±3.7 years.

Results: No significant change in serum calcium, serum 25OHD, BAP. PTH level rested also normal. Clinical significantly reduced the hyperalgesia after a mean of 6.7 weeks (6–12 weeks). Adverse events after infusion were flu-like syndrome transient 18%, arthromyalgias 9%, arterial hypertension 4.5%. No cardiac arrhytmias, no fractures. BMD changes at lombar, total hip and neck are presented in the Table 1.

Conclusions: In our experience, iv infusions of ZOL (5 mg) have shown to be effectively in increasing BMD. The other biologic parameters remained in normal level. The adverse effects only in the first administration without consequences.

Keywords: osteoporosis, Zoledronic acid, BMD.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: